Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone.
To assess the prognostic value of tumor necrosis in osteogenic sarcoma of bone, we designed a retrospective study of 18 patients with classic osteogenic sarcoma (OGS) in which several factors were considered as the common criteria of inclusion. Forty percent of patients with > or = 95% necrosis related to chemotherapy of their primary tumor experienced metastatic disease and/or tumor recurrence during their follow-up, while 50% of those with < 95% necrosis had a disease-free period of > or = 5 years. Tumor necrosis related to chemotherapy in OGS does not seem to represent, as a single predictor of disease-free survival, an accurate clinical prognostic indicator. Further clinical and epidemiologic studies are needed on larger series of patients with strict criteria of inclusion to confirm our results.
Zunino
J H
JH
Bone Research Department, Tissue Bank, University Hospital, Montevideo, Uruguay.
Johnston
J O
JO
D000293:Adolescent; D000328:Adult; D017209:Apoptosis; D001859:Bone Neoplasms / Q000473:pathology*; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D010020:Osteonecrosis / Q000175:diagnosis; D012516:Osteosarcoma / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies